SEC Form 8-K Summary
Business context and reporting period
This Form 8-K was filed by Anzu Special Acquisition Corp I, a Delaware special purpose acquisition company, on February 9, 2023. Although the request metadata identifies Envoy Medical, Inc., the filing itself names Anzu as the registrant. The filing concerns Anzu’s proposed extension of the deadline to complete an initial business combination.
Financial metrics and liquidity
The filing does not provide financial statements or clear values for revenue, profit, cash flow, margins, debt, liquidity, or other operating metrics.
Material changes versus the prior comparable period
- Anzu convened its special meeting of stockholders on February 9, 2023 and adjourned it without conducting any other business.
- The special meeting was rescheduled for February 21, 2023 at 9:30 a.m. Eastern Time.
Guidance, outlook, risks, and unusual items
The adjournment relates to stockholder consideration of a previously announced proposal to extend Anzu’s deadline to complete an initial business combination. The filing does not state whether the extension was approved or provide additional transaction terms, financing details, or completion certainty. As a SPAC, failure to complete a business combination within the applicable deadline could create material consequences, but the specific deadline and related terms are not stated in the provided filing text.
Item 7.01 and Exhibit 99.1 were furnished rather than filed under Section 18 of the Exchange Act and are not incorporated by reference into other filings solely by general incorporation language.
Key facts for investors to verify
- Verify the outcome of the February 21, 2023 special meeting.
- Verify the proposed revised deadline for completing an initial business combination.
- Review Exhibit 99.1 for the full press release and any voting, redemption, or extension conditions.
- Confirm whether the filing is relevant to Anzu Special Acquisition Corp I rather than Envoy Medical, Inc.
- Review subsequent filings for the status of Anzu’s business combination and any effects on public shares, warrants, or trust funds.